Results 251 to 260 of about 36,481 (278)

The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma

Biochimie, 2020
The hypoxic environment of melanoma results in CD73 upregulation on the surface of various tumor microenvironment (TME) cells including tumor cells, stromal cells and infiltrated immune cells. Consequently, CD73 through both enzymatic and none enzymatic functions affect melanoma progression.
Anvar Soleimani, Helale Kaboli Farshchi, Farshad Mirzavi, Parvin Zamani, Amir Ghaderi, Yousef Amini, Shadi Khorrami, Kazem Mashayekhi, Mahmoud Reza Jaafari   +8 more
openaire   +2 more sources

CD73 as a potential opportunity for cancer immunotherapy

Expert Opinion on Therapeutic Targets, 2018
Cancer cells apply various mechanisms to induce and enhance immune escape. The complex network of immune-response modulating factors in the tumor microenvironment is a reason for the difficulties encountered when attempting to treat many cancers. Adenosine is a potent immune-modulating factor that can be generated through the degradation of ATP by ...
Ghasem Ghalamfarsa, Mohammad Hossein Kazemi, Sahar Raoofi Mohseni, Ali Masjedi, Mohammad Hojjat-Farsangi, Gholamreza Azizi, Mehdi Yousefi, Farhad Jadidi-Niaragh   +7 more
openaire   +2 more sources

CD73 Inhibitors as Antitumor Agents

2023
5′-Ectonucleotidase (e5NT), a metalloenzyme incorporating two zinc ions in its structure, also known as CD73, hydrolyzes AMP to phosphate and adenosine. It is involved in several physiological and pathological processes, among which immune homeostasis, inflammation, tumor progression. The last decade saw the development of small molecule and monoclonal
Capasso, Clemente, Nocentini, Alessio, Supuran, Claudiu T.   +2 more
openaire   +2 more sources

T Cell Signalling Through CD73

Cellular Signalling, 1997
CD73 (ecto-5'-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.
R, Resta, L F, Thompson
openaire   +2 more sources

Discovery of AB680: A Potent and Selective Inhibitor of CD73

Journal of Medicinal Chemistry, 2020
Extracellular adenosine (ADO), present in high concentrations in the tumor microenvironment (TME), suppresses immune function via inhibition of T cell and NK cell activation. Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP → AMP) and CD73 (AMP → ADO).
Kenneth V. Lawson, Jaroslaw Kalisiak, Erick A. Lindsey, Eric T. Newcomb, Manmohan Reddy Leleti, Laurent Debien, Brandon R. Rosen, Dillon H. Miles, Ehesan U. Sharif, Jenna L. Jeffrey, Joanne B. L. Tan, Ada Chen, Sharon Zhao, Guifen Xu, Lijuan Fu, Lixia Jin, Tim W. Park, Wade Berry, Susanne Moschütz, Emma Scaletti, Norbert Sträter, Nigel P. Walker, Stephen W. Young, Matthew J. Walters, Uli Schindler, Jay P. Powers   +25 more
openaire   +2 more sources

CD73 (5′-Ectonucleotidase)

5′-Ectonucleotidase (e5NT), a metalloenzyme also known as CD73, hydrolyzes AMP to phosphate and adenosine. In mammalians, CD73 is involved in several physiological and pathological processes, among which immune homeostasis, inflammation, and tumor progression.
Supuran C. T., Capasso C.
openaire   +2 more sources

Evaluation of CD73 in lung cancer.

Journal of Clinical Oncology, 2017
e14525 Background: Immunotherapy has shown promising results in multiple forms of cancer including lung cancer patients. Treatment targeting alternative immune checkpoints may demonstrate value for specific cancers or in combination therapy with other immunotherapies or chemotherapeutic agents.
Hui Yu, Maya Amar, Christopher J Rivard, Kim Ellison, Leslie Rozeboom, Kenichi Suda, Kristine Brovsky, Fred R. Hirsch   +7 more
openaire   +1 more source

Novel CD73 Inhibitors for Treating Cancer

ACS Medicinal Chemistry Letters
Provided herein are novel CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
openaire   +2 more sources

Opportunities and Challenges for anti-CD73 Cancer Therapy

Immunotherapy, 2012
Biotherapy Center of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China and Department of Medicine, Cancer Therapy & Research Center, University of Texas Health Science Center, San Antonio, TX 78229, USA and Robert H Lurie Comprehensive Cancer Center, Department of Medicine – Division of Hematology/Oncology, Northwestern ...
openaire   +2 more sources

CD73

1997
A. Neil Barclay, Marion H. Brown, S.K. Alex Law, Andrew J. McKnight, Michael G. Tomlinson, P. Anton van der Merwe   +5 more
openaire   +1 more source